Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.

ABSTRACT:

Importance

Evidence is lacking from randomized clinical trials to guide the optimal approach for stereotactic ablative body radiotherapy (SABR) in patients with pulmonary oligometastases.

Objective

To assess whether single-fraction or multifraction SABR is more effective for the treatment of patients with pulmonary oligometastases.

Design, setting, and participants

This multicenter, unblinded, phase 2 randomized clinical trial of 90 patients across 13 centers in Australia and New Zealand enrolled patients with 1 to 3 lung oligometastases less than or equal to 5 cm from any nonhematologic malignant tumors located away from the central airways, Eastern Cooperative Oncology Group performance status 0 or 1, and all primary and extrathoracic disease controlled with local t

SUBMITTER: Siva S 

PROVIDER: S-EPMC8404145 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature